• Staging and Guidelines for HCC: NCCN, Barcelona, or Hong Kong?
• Surgical Options for HCC: When and Why?
• Role of Ablation: Should It Be Used As Primary Therapy For Early Stage HCC?
• Transarterial Therapies for HCC: Should It's Role Be Limited To Just The Unresectable?
• Systemic Treatments for HCC: Is There Really A Significant Benefit?
• Featured Abstract
• Tumor Board

 Moderators: Matthew Callstrom, MD, PhD & Afshin Gangi, MD, PhD  

• MSK Interventions: Palliation, Ablation, Consolidation
• Treatment of Spine Metastases with RFA: New Approaches 
• Abstract
• Role of Ablation in Orthopedic Oncology: A Surgeon's Perspective
• Hardware and Ablation In the Pelvis 
• Ablation Treatment of Desmoids: Is It More Effective Than Traditional Treatments?    
• Avoiding Complications in MSK Ablation   
• Tips and Tricks with MSK Ablation 
• Tumor Board                                                             

• Selective Internal Radiation Therapy for Cholangiocarcinom
• IO in Palliative Care for Old Cancer Patients
• IO in Breast Cancer Patients

• Medical Management of Pain: What An Astute Interventional Oncologist/Radiologist Can Do
• Percutaneous Nerve Blocks and Neurolysis
• Percutaneous Techniques for Pleural Effusion, Malignant Ascites, and Outlet Obstruction
• Palliative Embolization: Pain and Bleeding
• Percutaneous Ablation and Bone Augmentation for Pain Management

Best Case Presentation

• RFA
• MWA
• Cryo
• Navigation & Ablation
• cTACE
• DEB-TACE
• Y90
• Tumor Board

• Oncogenic Pathways & Their Relevance To Interventional Oncology
• Pathologic Changes & Prognostic Biomarkers in Tumor Ablation
• Image Guided Drug Delivery
• HSP90 As Therapeutic Targets in Combination Ablation Therapies & Molecular Mechanisms of Cell Survival After Thermal Ablation
• Angiogenesis
• Glycolysis & Its Importance In Cancer
• Pathological Changes Prognostic Biomarkers in Arterially Directed Therapies: SIRT/TACE
• Clinical & Translational Research Pathways for Molecular Therapies & Immunotherapies in HCC

• Science of CER
• CER in Procedural Oncology
• Resources for CER Research in IO
• Funding Opportunities for CER in Oncology

• Lung Cancer Screening
• Progression of Atypical Adenoma to Lung Adenocarcinoma
• Sublobar Resection versus Lobectomy for Primary Lung Cancer: Has the Standard Changed?
• SBRT Clinical Trial Update
• Lung Cancer Ablation
• Management of Multifocal Stage I Lung Cancer
• Local Therapy in the Setting of Metastatic Lung Cancer
• Biopsy of Lung Cancer in the World of Personalized Medicine

• Guidance, Navigation, Assessment, & Robotics 

Interventional Oncology Management of Hepatocellular Carcinoma - The Evidence from Asia

• Local Ablation
• Chemoembolization
• Radioembolization
• Management of HCC in Europe
• Is There A Role For Combination Therapies in HCC
• Trial Design in HCC: Principle and End Points

• Choosing Your Device & Know the Outcomes
• Lessions Learned from the Dark Side of Renal Ablation
• If Surgery Is the Standard, Where Does Ablation Fit In?
• Renal Tumor Board

• Assessment & Triage of NETs in the IO Clinic
• Systemic Drug Therapies: Which One When?
• When Is Surgery Beneficial In Metastatic NETs?
• PRRT: Integration with Liver-Directed Therapies
• Embolotherapy: Is There A Best Technique?
• Radioembolization of mNET

• Ablation: Kidney and Lung

• RFA/MW/Cryo/IRE

Resectable or Potentially Resectable Disease (Debate 1: Surgery vs. Ablation)

• Surgery Remains the Gold Standard for All CLM
• Ablation Should Replace Surgery For Selected CLM That Can Be Treated With Margins
• Role of PVE and Other Techniques As Bridge To Resection

Non-Resectable Disease

• What is New in Systemic Treatment for Stage IV CRC?
• Locoregional Therapy in CRC Mets: Timing and Results
• The Case for Integration of Locoregional Therapy with Systemic Therapy

Pulmonary Mets

• Resectable Pulmonary Mets Should Only Be Treated By Surgery
• SBRT Is All You Need For Pulmonary Mets
• Ablation Is The Best Option For Selected Pulmonary Metastases
• Tumor Board